查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1890966

Vyndaqel市场按适应症、疗效、支付方、分销管道、最终用户、年龄层和地区划分

Vyndaqel Market, By Indication, By Strength, By Payer, By Distribution Channel, By End User, By Age group, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计到 2025 年，Vyndaqel 市场价值将达到 83.7 亿美元，到 2032 年将达到 198.1 亿美元，2025 年至 2032 年的复合年增长率为 13.1%。

报告内容 报告详情
基准年： 2024 2025年市场规模： 83.7亿美元
历史数据时期： 2020-2024 预测期： 2025-2032
预测期间（2025-2032年）： 13.10% 2032 年的预测值： 198.1亿美元

全球Vyndaqel市场属于专注于tafamidis的专科製药领域。 tafamidis是一种突破性药物，用于治疗转甲状腺素类淀粉沉积症样变性（ATTR）。 ATTR是一种罕见但进行性疾病，其特征是转甲状腺素蛋白错误折迭和积累，会影响多个器官，尤其是心臟和周围神经。 Vyndaqel由辉瑞公司在收购其原研发公司后主要负责市场推广，现已成为治疗遗传性转甲状腺素类淀粉沉积症样变性（伴神经病变的hATTR-PN）和转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）的重要药物。

该药物作为一种转甲状腺素蛋白稳定剂，可防止四聚体转甲状腺素蛋白解离成单体，进而避免错误折迭形成淀粉样蛋白沉积。随着全球医疗体係日益重视罕见疾病治疗和改善复杂疾病患者的预后，Vyndaqel市场正获得显着成长。诊断能力的提升、医疗专业人员对ATTR症状认识的提高、各地区监管核准的扩大以及对罕见病精准医疗方法的日益关注，都显着推动了该市场的增长，使其成为全球专科药品市场的重要组成部分。

市场动态

全球Bindakel市场成长的主要驱动因素包括：转甲状腺素类淀粉沉积症样变性（ATTR）盛行率的上升、诊断调查方法的进步使得ATTR能够早期、准确地检测出来，以及医疗专业人员对该疾病多种表现形式（尤其是以往诊断不足的心臟表现）的认识不断提高。全球人口老化也是市场成长的重要因素，因为ATTR-CM主要影响老年患者，而野生型转甲状腺素类淀粉沉积症也日益被认为是老年人心臟衰竭的病因之一。孤儿药认定、快速审批核准和突破性治疗方法认定等监管支持正在加速市场渗透，而由于适应症的扩大和区域性核准的增加，目标患者群体也在不断扩大。此外，医疗保健领域在罕见疾病和专科药物方面的支出不断增加，加上已开发市场报销政策的改善，正在提高患者获得昂贵但能改变人生的治疗的机会。

然而，市场存在诸多限制因素。治疗费用每年可能超过20万美元，对医疗系统造成沉重的经济负担，并限制了病患的就医，尤其是在医疗预算有限的新兴市场。此疾病的罕见性限制了患者数量，而其复杂多样的症状与其他疾病相似，使得诊断极具挑战性，导致诊断和治疗启动的延迟。来自替代治疗方法的竞争，例如新兴的基因疗法和其他正在研发中的缓解疾病疗法，对市场占有率构成潜在威胁。这种特殊药物的生产复杂性和供应链挑战可能会影响其供应和定价。然而，透过扩大诊断意识项目，可以识别出先前未确诊的患者，尤其是在ATTR认知度仍然较低的医疗资源匮乏地区，这为患者带来了巨大的机会。伴随诊断和生物标记的开发有望简化患者的识别和监测流程。此外，将适应症扩展到其他ATTR症状和疾病早期阶段，可显着增加符合治疗条件的患者数量。

本次调查的主要特点

  • 本报告对全球 Vyndaqel 市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和复合年增长率百分比。
  • 他还重点介绍了各个细分市场的潜在商机，并说明了该市场具有吸引力的投资提案矩阵。
  • 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
  • 该研究根据以下参数对全球 Vindakeer 市场的主要企业进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
  • 本研究涵盖的主要企业包括辉瑞公司。
  • 本报告的研究结果将使负责人和经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • 全球Vyndaqel市场报告面向该行业的各类相关人员，包括投资者、供应商、产品製造商、经销商和新参与企业。
  • 相关人员可以透过分析全球 Bindoxel 市场所使用的各种策略矩阵轻鬆做出决策。

目录

第一章 研究目标与前提条件

  • 调查目的
  • 先决条件
  • 简称

第二章 市场范围

  • 报告概述
    • 市场定义和范围
  • 执行摘要

第三章：市场动态、监理及趋势分析

  • 市场动态
  • 司机
  • 抑制因素
  • 机会
  • 影响分析
  • 法规环境
  • 产品上市及核准
  • PEST分析
  • 波特分析
  • 併购趋势
  • 产业趋势

4. 2020-2032年全球Vyndaqel市场依适应症划分

  • 野生型转甲状腺素蛋白介导的类淀粉沉积症心肌病（ATTR-CM，野生型）
  • 遗传性转甲状腺素蛋白介导的类淀粉沉积症心肌病（ATTR-CM，变异型）
  • 转甲状腺素蛋白介导的类淀粉沉积症神经病变（ATTR-PN/FAP）

5. 2020-2032年全球Vyndaqel市场依效力划分

  • 20mg
  • 61mg

6. 2020-2032年全球Vyndaqel市场按支付方划分

  • 民众
  • 私人的
  • 自费/实际费用

7. 2020-2032年全球Vyndaqel市场按分销管道划分

  • 医院药房
  • 专科药房/网路药房
  • 零售药房

8. 2020-2032年全球Vyndaqel市场（依最终用户划分）

  • 医院
  • 心臟类淀粉沉积症中心
  • 门诊手术中心
  • 居家医疗设施

9. 2020-2032年全球Vyndaqel市场依年龄组别划分

  • 成年人（18岁以上）
  • 老年人（65岁以上）

第十章 全球Vyndaqel市场（按地区划分），2020-2032年

  • 北美洲
    • 美国
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲国家
  • 欧洲
    • 德国
    • 英国
    • 西班牙
    • 法国
    • 义大利
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
    • ASEAN
    • 亚太其他地区
  • 中东
    • GCC
    • 以色列
    • 其他中东国家
  • 非洲
    • 南非
    • 北非
    • 中非

第十一章 竞争格局

  • Pfizer Inc.

第十二章 分析师建议

  • 机会
  • 一致的机会地图

第十三章 参考文献与调查方法

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI8971

Vyndaqel Market is estimated to be valued at USD 8.37 Bn in 2025 and is expected to reach USD 19.81 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.1% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 8.37 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 13.10% 2032 Value Projection: USD 19.81 Bn

The global Vyndaqel market represents a specialized pharmaceutical segment focused on tafamidis, a breakthrough medication developed for treating transthyretin amyloidosis (ATTR), a rare but progressive disease characterized by the misfolding and accumulation of transthyretin proteins in various organs, particularly the heart and peripheral nerves. Vyndaqel, marketed primarily by Pfizer following their acquisition of the drug's original developer, has emerged as a critical therapeutic intervention for both hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) and transthyretin amyloid cardiomyopathy (ATTR-CM).

The drug functions as a transthyretin stabilizer, preventing the dissociation of tetrameric transthyretin into monomers that subsequently misfold and form amyloid deposits. As healthcare systems worldwide increasingly recognize the importance of addressing rare diseases and improving patient outcomes for complex conditions, the Vyndaqel market has gained substantial momentum. The market's growth trajectory is significantly influenced by enhanced diagnostic capabilities, increased awareness among healthcare professionals about ATTR manifestations, expanding regulatory approvals across different regions, and the growing emphasis on precision medicine approaches for rare disease management, positioning this market as a crucial component of the global specialty pharmaceuticals landscape.

Market Dynamics

The global Vyndaqel market is primarily driven by the increasing prevalence of transthyretin amyloidosis, improved diagnostic methodologies that enable earlier and more accurate detection of ATTR, and growing awareness among healthcare professionals about the disease's varied presentations, particularly its cardiac manifestations which were historically underdiagnosed. The aging global population contributes significantly to market growth, as ATTR-CM predominantly affects elderly patients, with wild-type transthyretin amyloidosis becoming more recognized as a cause of heart failure in older adults. Regulatory support through orphan drug designations, fast-track approvals, and breakthrough therapy designations has accelerated market penetration, while expanded indications and geographical approvals continue to broaden the addressable patient population. Additionally, increased healthcare spending on rare diseases and specialty pharmaceuticals, coupled with improved reimbursement policies in developed markets, has enhanced patient access to this costly but life-changing therapy.

However, the market faces substantial restraints including the extremely high cost of treatment, which can exceed USD 200,000 annually, creating significant financial barriers for healthcare systems and limiting patient access, particularly in emerging markets with constrained healthcare budgets. The rarity of the disease results in a limited patient population, while diagnostic challenges persist due to the disease's complex and varied presentations that can mimic other conditions, leading to delayed diagnosis and treatment initiation. Competition from alternative treatment approaches, including emerging gene therapies and other disease-modifying treatments in development, poses potential market share threats. Manufacturing complexities and supply chain challenges for this specialized medication can impact availability and pricing. Nevertheless, significant opportunities exist through expanding diagnostic awareness programs that could identify previously undiagnosed patients, particularly in underserved geographical regions where ATTR recognition remains limited. The development of companion diagnostics and biomarkers could streamline patient identification and monitoring, while potential label expansions to additional ATTR manifestations or earlier disease stages could substantially increase the treatable patient population.

Key Features of the Study

  • This report provides in-depth analysis of the global Vyndaqel market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global Vyndaqel market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key company covered as a part of this study include Pfizer Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global Vyndaqel market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Vyndaqel market

Market Segmentation

  • Indication Insights (Revenue, USD Bn, 2020 - 2032)
    • Wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, wild-type)
    • Hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, variant)
    • Transthyretin-mediated amyloidosis polyneuropathy (ATTR-PN/FAP)
  • Strength Insights (Revenue, USD Bn, 2020 - 2032)
    • 20 mg
    • 61 mg
  • Payer Insights (Revenue, USD Bn, 2020 - 2032)
    • Public
    • Private
    • Self-pay/Out-of-pocket
  • Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospital pharmacies
    • Specialty/Online pharmacies
    • Retail pharmacies
  • End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospitals
    • Cardiac Amyloidosis Centers
    • Ambulatory Surgical Centers
    • Homecare Settings
  • Age Group Insights (Revenue, USD Bn, 2020 - 2032)
    • Adults (>=18 yrs)
    • Elderly (>=65 yrs)
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Pfizer Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Vyndaqel Market, By Indication
    • Global Vyndaqel Market, By Strength
    • Global Vyndaqel Market, By Payer
    • Global Vyndaqel Market, By Distribution Channel
    • Global Vyndaqel Market, By End User
    • Global Vyndaqel Market, By Age group
    • Global Vyndaqel Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Vyndaqel Market, By Indication, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, wild-type)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, variant)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Transthyretin-mediated amyloidosis polyneuropathy (ATTR-PN/FAP)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Vyndaqel Market, By Strength, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • 20 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • 61 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Vyndaqel Market, By Payer, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Public
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Private
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Self-pay/Out-of-pocket
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Vyndaqel Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Specialty/Online pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Vyndaqel Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Cardiac Amyloidosis Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Homecare Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Vyndaqel Market, By Age group, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Adults (>=18 yrs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Elderly (>=65 yrs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Vyndaqel Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Payer, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

11. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

12. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

13. References and Research Methodology

  • References
  • Research Methodology
  • About us